William Mack & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

William Mack & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$313K	Sell	630 -39	-6%	-$17.3K	0.11%	75
2026 Q1	$299K	Sell	669 -13	-2%	-$6.06K	0.17%	57
2025 Q4	$309K	Hold	682	–	–	0.15%	59
2025 Q3	$267K	Hold	682	–	–	0.14%	64
2025 Q2	$304K	Hold	682	–	–	0.19%	58
2025 Q1	$331K	Hold	682	–	–	0.28%	48
2024 Q4	$275K	Buy	+682	New	+$316K	0.29%	51

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

William Mack & Associates's VRTX Position: Q2 2026 in Review

William Mack & Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 5.8% in Q2 2026, selling an estimated $17.3K and leaving 630 shares worth $313K. The position accounts for 0.11% of the portfolio, ranked #75.

William Mack & Associates first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $331K in Q1 2025. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

William Mack & Associates held 630 shares of Vertex Pharmaceuticals worth $313K as of Q2 2026.
William Mack & Associates sold 39 Vertex Pharmaceuticals shares in Q2 2026, an estimated $17.3K.
Vertex Pharmaceuticals made up 0.11% of William Mack & Associates's portfolio in Q2 2026, its #75 holding.
William Mack & Associates first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
William Mack & Associates's Vertex Pharmaceuticals position peaked at $331K in Q1 2025.
1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on William Mack & Associates's 13F filing for Q2 2026, filed 10 Jul 2026.